SS-31 vs MOTS-c — Mitochondria-Targeted Synthetic vs Endogenous MDP
SS-31 (elamipretide) is a synthetic cardiolipin-stabilising peptide; MOTS-c is an endogenous mitochondrial-derived peptide. Same organelle, different origins, different mechanisms.
| Feature | SS-31 | MOTS-c |
|---|---|---|
| Origin | Synthetic tetrapeptide (D-Arg-2',6'-dimethylTyr-Lys-Phe-NH2) | Endogenous 16-aa peptide encoded within mitochondrial DNA (MT-RNR1) |
| Development route | Pharmaceutical — Stealth BioTherapeutics; INN elamipretide | Endogenous discovery — Lee et al., 2015 Cell Metabolism |
| Molecular target | Cardiolipin at the inner mitochondrial membrane | AMPK activation (indirect); direct receptor still under investigation |
| Where it acts | Physically localises to the inner mitochondrial membrane; stabilises electron-transport-chain geometry | Circulating hormone; acts on skeletal muscle, liver, adipose |
| Primary research indication | Mitochondrial myopathies, Barth syndrome, age-related mitochondrial dysfunction | Metabolic — insulin sensitivity, mitochondrial biogenesis, exercise mimetic |
| Clinical trial stage | Phase 2/3 in Barth syndrome, primary mitochondrial myopathy; approved by FDA for Barth syndrome (2024, Forzinity) | Preclinical + biomarker studies; no phase-2/3 outcome trials |
| Route in research | Subcutaneous | Intraperitoneal (rodent); not established in humans |
| UK MHRA status | Not authorised (elamipretide approved by FDA in 2024 as Forzinity; UK MHRA has not followed) | Unlicensed research compound |
| Class | Mitochondria-targeted synthetic peptide (MTP) | Mitochondrial-derived peptide (MDP) — endogenous |
Different classes, one organelle
The critical distinction to internalise: SS-31 is a synthetic drug you add, MOTS-c is an endogenous hormone your body already makes. They both concern mitochondria, but their intervention logic differs at the root.
SS-31 (Chavez 2020, PNAS, PMID 32554501) is a small synthetic tetrapeptide that carries a positive charge and localises to the inner mitochondrial membrane. Its target is cardiolipin — the phospholipid that gives the inner membrane its characteristic geometry and holds electron-transport-chain complexes in the right orientation for efficient ATP production. In dysfunctional mitochondria, cardiolipin is peroxidised, the membrane geometry collapses, and ETC efficiency crashes. SS-31 physically re-stabilises this. It's structural rescue.
MOTS-c (Lee 2015, Cell Metab, PMID 25738459) is a 16-amino-acid peptide encoded within your own mitochondrial DNA, secreted into circulation, and acting on distant tissues as an endocrine signal. Its dominant systemic effect is AMPK activation in skeletal muscle and liver — improving insulin sensitivity, shifting metabolism toward oxidative phosphorylation, and acting as an exercise mimetic. It's a signalling molecule, not a structural repair.
Regulatory divergence
SS-31 (elamipretide) received FDA approval in 2024 for Barth syndrome, marketed as Forzinity. That is a single-indication approval for a rare mitochondrial disease. UK MHRA has not followed with an authorisation as of 2026-08. All other uses — general anti-ageing, athletic performance — are off-label / investigational.
MOTS-c has no regulatory authorisation anywhere. It is sold as a research chemical through grey-market channels. Its evidence base is entirely preclinical and biomarker-level in humans.
Combining them
No published trial has tested SS-31 + MOTS-c coadministration in humans. The theoretical rationale is complementary — SS-31 restores mitochondrial architecture, MOTS-c signals metabolic uplift downstream — but this is a research hypothesis, not established practice. See our SS-31 + MOTS-c cardio stack review for the current published-evidence position.
UK regulatory context
Neither is a licensed medicine in the UK. Any promotion as anti-ageing or cardio-protective products would fall under MHRA rules on advertising unlicensed medicines — see our POM advertising hub. The elamipretide FDA approval for Barth syndrome does NOT authorise UK marketing or general clinical use.
Related pages
- SS-31 monograph
- MOTS-c monograph
- Humanin monograph — endogenous cytoprotective MDP
- MOTS-c vs Humanin comparison
- SS-31 + MOTS-c cardio stack review
- Mitochondrial-derived peptides map
- Mitochondrial-derived peptides glossary entry
Verdict — research-question matching
Both address mitochondrial function but they're not competitors. SS-31 is a structural peptide that physically stabilises cardiolipin at the inner mitochondrial membrane — a drug-like pharmacological intervention with the first FDA approval (2024, Barth syndrome). MOTS-c is an endogenous signalling molecule the body already produces, whose levels decline with age. The interesting research question is whether they act synergistically (SS-31 restores mitochondrial architecture; MOTS-c signals downstream) — but no controlled study has tested that combination in humans.
References
Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.
- Birk AV, Liu S, Soong Y, et al.. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013;24(8) :1250-1261 doi:10.1681/ASN.2012121216 · PMID: 23813215
- Chavez JD, Tang X, et al.. Mitochondrial protein interaction landscape of SS-31. Proceedings of the National Academy of Sciences. 2020;117(26) :15363-15373 · PMID: 32554501
- Lee C, Zeng J, Drew BG, et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3) :443-454 doi:10.1016/j.cmet.2015.02.009 · PMID: 25738459
- Zheng Y, Wei Z, et al.. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. 2023;14 :1120533 · PMID: 36761202
Continue reading
Epitalon + Humanin + MOTS-c — Research Evidence Review: Mitochondrial & Telomeric Mechanisms
Three-peptide longevity research stack targeting telomerase activation, mitochondrial unfolded-protein response and metabolic ageing. Full dosing protocol and UK regulatory note.
MOTS-c + AOD-9604 — Research Evidence Review: Mitochondrial & Lipolytic Mechanisms
Mitochondrial-derived peptide + GH lipolytic fragment research stack — exercise-mimetic metabolic protocol without GH-axis perturbation.
SS-31 + Humanin — Research Evidence Review: Mitochondrial Mechanisms
Mitochondrial-targeted research stack — SS-31 (Elamipretide) and Humanin. Cardiolipin stabilisation and mitochondrial unfolded protein response (MUPR).
SS-31 (Elamipretide) — Cardiolipin-Targeted Mitochondrial Peptide
SS-31 (Elamipretide) is a D-amino-acid tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, stabilising the electron transport chain and reducing pathological ROS.
MOTS-c — Mitochondrial Open Reading Frame 12S rRNA-c
MOTS-c is a mitochondrial-derived peptide that activates AMPK, mimics exercise-induced gene expression, and declines with age — linking metabolic fitness to mitochondrial output.
MOTS-c vs AOD-9604 — Mitochondrial vs GH-Fragment Fat-Loss Comparison
Research comparison of MOTS-c and AOD-9604: mechanisms, dosing, and evidence for fat-loss and metabolic research protocols.